(Q33613143)

English

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies (English)

1 reference

Europe PubMed Central

28 July 2017

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Alan Sinclair

1

1 reference

Europe PubMed Central

28 July 2017

Bruce Bode

2

1 reference

Europe PubMed Central

28 July 2017

Stewart Harris

3

1 reference

Europe PubMed Central

28 July 2017

Ujjwala Vijapurkar

4

1 reference

Europe PubMed Central

28 July 2017

Cristiana Mayer

5

1 reference

Europe PubMed Central

28 July 2017

Albert Fung

6

1 reference

Europe PubMed Central

28 July 2017

Wayne Shaw

7

1 reference

Europe PubMed Central

28 July 2017

Keith Usiskin

8

1 reference

Europe PubMed Central

28 July 2017

Mehul Desai

9

1 reference

Europe PubMed Central

28 July 2017

Gary Meininger

10

1 reference

Europe PubMed Central

28 July 2017

publication date

18 April 2014

1 reference

Europe PubMed Central

28 July 2017

BMC Endocrine Disorders

1 reference

Europe PubMed Central

28 July 2017

14

1 reference

Europe PubMed Central

28 July 2017

37

1 reference

Europe PubMed Central

28 July 2017

https://scigraph.springernature.com/pub.10.1186/1472-6823-14-37

0 references

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Emergency hospitalizations for adverse drug events in older Americans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4021426

14 July 2018

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-14-37

21 January 2018

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-14-37

21 January 2018

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-14-37

21 January 2018

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-14-37

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-14-37

21 January 2018

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1186%2F1472-6823-14-37

21 January 2018

Diabetes in the elderly

1 reference

https://pubmed.ncbi.nlm.nih.gov/24742013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/24742013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1472-6823-14-37

1 reference

Europe PubMed Central

28 July 2017

Dimensions Publication ID

0 references

release_ivcz34txmnbtxpywa43v4qtn7y

1 reference

https://api.fatcat.wiki/v0/release/ivcz34txmnbtxpywa43v4qtn7y

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33613143&oldid=1840391802"